[1] |
ZHU Zhipeng, LYU Qiang, YE Xiaofei, GUO Xiaojing.
Disproportionality of Adverse Events to KRAS G12C Inhibitors Based on the FAERS Database
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 297-304.
|
[2] |
LIU Chenpei, DU Yupeng, LIN Yan.
One Case of Anemia Caused by Finerenone Tablets
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 334-336.
|
[3] |
YU Li, TAN Xiying.
One Case of Acute Hepatic Injury Caused by Ioversol Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 343-345.
|
[4] |
WANG Songlan, SUN Ying, CHEN Aiqun, JI Liwei.
One Case of Acute Kidney Injury Induced by Evolocumab Injection in a Patient with Chronic Kidney Disease after Renal Transplantation
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(2): 221-223.
|
[5] |
NIE Xiaolu, ZHAO Houyu, HUO Donghui, YAN Aixia, SUN Feng, PENG Xiaoxia, NI Xin, ZHAN Siyan.
Pediatric Drug-Induced Immune Thrombocytopenia Based on Real World Data and Quantitative Structure-Activity Relationship
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 16-22.
|
[6] |
JIA Juanjuan, SUN Jiabei, ZHANG Wenzai, SUN Deyang, SHI Yaqin, HUANG Haiwei.
Biological Distribution of 99mTc-DMSA Injection
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 47-52.
|
[7] |
YAO Jing, LIAN Xiaofang, ZUO Limin, GUO Xin, LIU Huiyi, GU Yongsheng, JIA Qingying, HUANG Haiwei.
Determination of Contents of 15 Elemental Impurities in Kits of Dimercaptosuccinate Acid and Stannous Chloride for Injection by ICP-MS
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 53-57.
|
[8] |
ZHAO Qiuyue, WEI Hongtao, LI Dandan, YAN An, DI Xuan.
Adverse Reactions of Argatroban in the Treatment of Ischemic Stroke Leading to Gastrointestinal Bleeding
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 88-92.
|
[9] |
WEI Manli, LYU Linyan, ZHENG Zhiyuan, YIN Jiye, MAI Zhixiong.
Preclinical genotoxicity evaluation of xueshuantong injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1014-1018.
|
[10] |
WANG Yijin, TANG Jing, YANG Chao, XU Kai, ZHANG Mengdie, GAO Jian, WU Xiaoli, ZHANG Yue, NIU Xiaobing, JIANG Hesong, MAO Fei, ZHOU Shan, JIANG Xi, GUO Zhongying, SUN Su'an, XU Ming, XU Zongyuan, WANG Hengbing, LI Xin, FU Guangbo.
Clinical research of submucosal low-dose gemcitabine injection combined with transurethral resection of bladder tumor in the treatment of medium-high risk non-muscle invasive bladder cancer
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1044-1050.
|
[11] |
LIU Ting, CAO Zhongqiang, HE Wenjia, YUAN Xiuli, CHEN Zebin, LI Xuejuan.
One case of acute severe pancreatitis caused by pegaspargase and its etiology
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1075-1077.
|
[12] |
LIU Yi, LIU Xiaoqiang, YAO Xiao, LI Xuantang, GUO Xianhui, GENG Ying, PEI Yusheng.
Clinical compatibility of bromhexine injectable preparations
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 884-887.
|
[13] |
WEI Fenfang, WU Wenyu, LI Limin, TANG Biyu, WU Jianru.
Foreign methods for benefit-risk assessment of pharmaceutical products
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 900-905.
|
[14] |
WANG Yuxi, ZHANG Zonglin, WANG Yingli, CHEN Yafei, LI Junsheng, HUO Yanfei, XIE Yanjun, LIU Wenqi.
560 cases of adverse drug reaction/event caused by Mailu Shutong pills
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(8): 921-924.
|
[15] |
WANG Dan, DONG Duo, TIAN Chunhua.
Course of development of pharmocovigilance systems in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(7): 735-740.
|